Login / Register The Most Trusted Name in Medical Education

Infectious Disease

Elsevier CME is committed to providing the topics necessary to stay up-to-date in the field of infectious diseases.

ASM 116x140

Addressing the Urgent Threat: Strategies for Combating Hard-To-Treat Bacterial Infections

Format: Webcast

In the United States, as many as 2 million patients are annually diagnosed with antibiotic-resistant Gram-positive or Gram-negative (GP/GN) infections. Unfortunately, the development of novel antibiotics has lagged dangerously behind the emergence of resistant infections, leaving these patients with limited treatment options. Recently, several novel antibiotics have been approved, and more are in the clinical pipeline, many of which have proven to be particularly effective in patients with harder-to-treat GP and/or GN pathogens. However, in the absence of the judicious use of these new antibiotics, acquired resistance to these new agents is inevitable. This archived symposium will provide participants with the opportunity to review the clinical utility of new and investigational antimicrobials while also focusing on strategies to promote careful, appropriate antibiotic utilization. Interactive patient case scenarios will allow clinicians to apply acquired knowledge of antibiotic use to real-world examples of treating patients with GP/GN infections.

Take Course »

Credits: 2.0 AMA PRA Category 1 Credits™
910703 116 x 140

Current and Future Therapies for Cytomegalovirus (CMV) Infection

Format: Webcast

Cytomegalovirus (CMV) infection remains a frequent complication in hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT) recipients. In addition to causing a variety of end-organ diseases, CMV infection is also associated with rejection after SOT and with graft versus host disease (GVHD) after HSCT, as well as with increased risk of secondary bacterial and fungal infections. Antiviral prophylaxis, more commonly used after SOT, is effective against direct and indirect effects of CMV infection, but may lead to overtreatment. Preemptive therapy, more commonly used after HSCT, is based on surveillance, and targets therapy to patients at highest risk. Several antiviral agents are currently available for CMV management; however, their use may be associated with myelosuppression and nephrotoxicity. Novel antiviral therapies with different mechanisms of action are in late-stage development and hold the promise of reducing CMV-related morbidity and mortality.

Take Course »

Credits: 1.0 AMA PRA Category 1 Credit(s)™